









Markets
/
Stocks
/
nasdaq-tmdx
/

Transmedics Group Inc

TMDX

131.540USD

-4.250-3.13%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

4.49BMarket Cap

48.94P/E TTM



Transmedics Group Inc

131.540

-4.250-3.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Transmedics Group Inc

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Transmedics Group Inc's Score

Industry at a Glance

Industry Ranking

19 / 210

Overall Ranking

88 / 4618

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

145.200

Target Price

+6.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Transmedics Group Inc Highlights

StrengthsRisks

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 372.44% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 48.60, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 37.83M shares, decreasing 17.46% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 247.40K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 9.34, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 143.82M, representing a year-over-year increase of 32.24%, while its net profit experienced a year-over-year increase of 476.83%.

Score

Industry at a Glance

Previous score

9.34

Change



Financials

8.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Transmedics Group Inc's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 4.36, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 48.60, which is 4264.29% below the recent high of 2121.04 and 1081.81% above the recent low of -477.16.

Score

Industry at a Glance

Previous score

4.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 19/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Transmedics Group Inc is 147.50, with a high of 170.00 and a low of 115.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

145.200

Target Price

+6.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Transmedics Group Inc

TMDX

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 9.04, which is higher than the Healthcare Equipment & Supplies industry's average of 6.65. Sideways: Currently, the stock price is trading between the resistance level at 145.87 and the support level at 112.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.32

Change

-0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

3.411

Buy

RSI(14)

62.823

Neutral

STOCH(KDJ)(9,3,3)

73.377

Sell

ATR(14)

7.613

High Vlolatility

CCI(14)

82.582

Neutral

Williams %R

28.681

Buy

TRIX(12,20)

0.574

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

132.762

Sell

MA10

128.281

Buy

MA20

120.956

Buy

MA50

117.139

Buy

MA100

119.962

Buy

MA200

102.867

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 110.97%, representing a quarter-over-quarter decrease of 10.52%. The largest institutional shareholder is The Vanguard, holding a total of 3.59M shares, representing 10.50% of shares outstanding, with 2.87% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

4.73M

-2.02%

Fidelity Management & Research Company LLC

4.63M

-0.71%

The Vanguard Group, Inc.

Star Investors

3.59M

+0.59%

State Street Investment Management (US)

1.29M

-1.34%

Macquarie Investment Management

952.11K

-14.66%

Fidelity International

854.95K

-13.22%

Driehaus Capital Management, LLC

854.04K

+9.67%

Geode Capital Management, L.L.C.

804.65K

+1.42%

Two Sigma Investments, LP

692.64K

+2554.00%

Hood River Capital Management LLC

679.85K

-14.57%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 5.33, which is higher than the Healthcare Equipment & Supplies industry's average of 4.56. The company's beta value is 2.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.